Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
0(0%)
Results Posted
100%(6 trials)

Phase Distribution

Ph phase_3
2
33%
Ph phase_2
4
67%

Phase Distribution

0

Early Stage

4

Mid Stage

2

Late Stage

Phase Distribution6 total trials
Phase 2Efficacy & side effects
4(66.7%)
Phase 3Large-scale testing
2(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(6)

Detailed Status

Completed6

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 24 (66.7%)
Phase 32 (33.3%)

Trials by Status

completed6100%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_3

Compound Sodium Alginate Double Action Chewable Tablet Symptomatic Relief Study

NCT01869491
completedphase_2

A Study to Evaluate the Efficacy and Safety of Ivermectin in COVID-19 Prevention

NCT05305560
completedphase_3

Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Three-times Weekly Dosing in Dialysis (ASCEND-TD)

NCT03400033
completedphase_2

Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough

NCT03282591
completedphase_2

Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Chronic Pruritus of Unknown Origin

NCT03841331
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT01869491Phase 3

Compound Sodium Alginate Double Action Chewable Tablet Symptomatic Relief Study

Completed
NCT05305560Phase 2

A Study to Evaluate the Efficacy and Safety of Ivermectin in COVID-19 Prevention

Completed
NCT03400033Phase 3

Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Three-times Weekly Dosing in Dialysis (ASCEND-TD)

Completed
NCT03282591Phase 2

Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough

Completed
NCT03841331Phase 2

Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Chronic Pruritus of Unknown Origin

Completed
NCT03343639Phase 2

Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Plaque Psoriasis

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6